HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Post-Pandemic Stocks

922.671

+26.1432.92%

Number of Gainers:11

Number of Losers:5

Number of Flat:2

PE:- -

High:932.797

Open:893.740

Low:891.998

Close:896.528

Loading ...

Xinhua Pharmaceutical Gets Nod to Become Rights Holder of Epalrestat Tablets

MT Newswires Live

CSPC Pharmaceutical Gets US FDA Nod for Cardiac Drug Trial

MT Newswires Live

Fosun Pharma Gets Nod to Trial Alopecia Drug in US

MT Newswires Live

CSPC Pharmaceutical - Syh2046 Tablets Obtains Clinical Trial Approval in U.S. by FDA

THOMSON REUTERS

Ascletis Pharma to Present Results of Preliminary Studies on Anti-Obesity Drug

MT Newswires Live

BRIEF-Sihuan Pharma Repurchases 20 Million Shares At Average Price Of HK$0.7342 Per Share

Sihuan Pharma - Repurchased 20 Mln Shares at Average Price of HK$0.7342 per Share

THOMSON REUTERS

Sihuan Pharmaceutical Files Next Day Disclosure Return to HKEX Announcing Repurchase of 20 Million Shares at HKD 0.73-0.74 Each

BRIEF-Sihuan Pharma Says On 30 April And 2 May Repurchased 3.4 Million Shares

CSPC Pharmaceutical Gets US FDA Nod for Metabolism Disease Drug Trial

MT Newswires Live

CSPC Pharmaceutical's Phase 2/3 trial for Anti-Cancer Drug Meets Primary Endpoints

MT Newswires Live

Sihuan Pharma - on 30 April and 2 May Repurchased 3.4 Mln Shares at Average Price of HK$0.71 per Share

THOMSON REUTERS

BRIEF-Ob Holdings Says Unit Entered Into Letters Of Intent With Units of CSPC Pharmaceutical Group

CSPC Pharmaceutical - Jmt202 Obtains Clinical Trial Approval in U.S.

THOMSON REUTERS

Ob Holdings - Letters of Intent Entered Into by Orient Biotech With Units of CSPC Pharmaceutical Group

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1515/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":922.6707,"timestamp":1747037290222,"preClose":896.528,"halted":0,"volume":639468156,"delay":0,"changeRate":0.02916,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":26.1427,"latestTime":"05-12 16:00:00","open":893.73975,"high":932.79736,"low":891.99774,"amount":5930868565.5,"amplitude":0.045508,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747099800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1747013400000,1747022400000],[1747026000000,1747036800000]],"pbRate":1.585523,"peRate":21.198848,"turnoverRate":0.008452,"increases":11,"decrements":6,"flats":1,"marketCap":634840009216,"floatMarketCap":524045002368},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":932.79736,"amplitude":0.045508,"preClose":896.528,"low":891.99774,"pbRate":"1.585523","latestPrice":922.6707,"volume":639468156,"delay":0,"open":893.73975,"prevYearClose":787.97723,"prevWeekClose":896.528,"prevMonthClose":903.998,"prevQuarterClose":870.015,"fiveDayClose":921.416,"twentyDayClose":756.168,"sixtyDayClose":879.539,"secType":"PLATE","market":"HK","turnoverRate":0.008452,"peRate":21.198848,"marketCap":634840009216,"floatMarketCap":524045002368,"timestamp":1747037290222,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":11,"down":5,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534212112","title":"Xinhua Pharmaceutical Gets Nod to Become Rights Holder of Epalrestat Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2534212112","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534212112?lang=en_us&edition=fundamental","pubTime":"2025-05-12 17:08","pubTimestamp":1747040916,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  obtained approval from China's National Medical Products Administration to become the marketing license holder of epalrestat tablets, according to a Hong Kong Stock Exchange disclosure on May 9.The pharmaceutical company obtained the rights to the drug from Jiangsu Dongke Kangde Pharmaceutical in August 2023.The drug is indicated for use in connection with diabetic neuropathy, the disclosure said.Xinhua Pharma's Hong Kong shares closed less than 2% higher.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0164","BK1515","00719","000756","BK0239","BK1191"],"gpt_icon":0},{"id":"2534229474","title":"CSPC Pharmaceutical Gets US FDA Nod for Cardiac Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2534229474","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534229474?lang=en_us&edition=fundamental","pubTime":"2025-05-12 14:46","pubTimestamp":1747032387,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  has received approval to conduct clinical trials of its SYH2046 tablets from the US Food and Drug Administration, a Friday Hong Kong bourse filing said.The indication for the approval is heart failure after acute myocardial infarction.The pharmaceutical company had obtained clinical trial approval for the drug from China's National Medical Products Administration in April.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","LU1008478684.HKD","IE00BZ08YR35.GBP","SG9999004220.SGD","IE00BZ08YT58.USD","LU0072913022.USD","LU0501845795.SGD","BK1521","LU1152091168.USD","LU1960683339.HKD","LU1226287875.USD","IE0008369823.USD","LU0140636845.USD","BK1515","LU0067412154.USD","LU1993786604.SGD","LU1226287792.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU1226287529.USD","LU1152091754.HKD","LU1226288253.USD","LU0326950275.SGD","LU0880133367.SGD","LU1226288170.HKD","LU1807302812.USD","IE0008368742.USD","01093","IE00B031HY20.USD","LU1951186391.HKD","IE00BZ08YS42.EUR"],"gpt_icon":0},{"id":"2534209262","title":"Fosun Pharma Gets Nod to Trial Alopecia Drug in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2534209262","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534209262?lang=en_us&edition=fundamental","pubTime":"2025-05-12 11:54","pubTimestamp":1747022063,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  unit, Shanghai MicroH Therapeutics, will conduct a phase I clinical trial on LBP-ShC4 in the US after receiving approval from the US Food and Drug Administration, according to a Hong Kong Stock Exchange filing on May 9.The drug is intended to be used for the treatment of androgenetic alopecia, the filing said.The Chinese pharmaceutical company invested 17 million yuan in the research and development of the drug as of April.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00656","BK1593","BK0060","BK1515","BK0188","BK0239","BK0187","BK0196","600196","BK1191","02196","BK0028","BK0096","BK0175","BK1230","BK0183","BK0012"],"gpt_icon":0},{"id":"2534105112","title":"CSPC Pharmaceutical -  Syh2046 Tablets Obtains Clinical Trial Approval in U.S. by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2534105112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534105112?lang=en_us&edition=fundamental","pubTime":"2025-05-09 18:29","pubTimestamp":1746786553,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250509:nFWN3RH1FQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999004220.SGD","IE00B5MMRT66.SGD","IE00BZ08YT58.USD","LU1152091168.USD","LU0501845795.SGD","LU0326950275.SGD","LU1951186391.HKD","IE00B031HY20.USD","IE0008369823.USD","BK1191","IE00BZ08YS42.EUR","LU1960683339.HKD","LU0067412154.USD","LU1807302812.USD","LU1008478684.HKD","BK1521","01093","LU1226288253.USD","LU1226287792.SGD","LU1226287875.USD","LU0140636845.USD","IE00BZ08YR35.GBP","LU1993786604.SGD","IE0008368742.USD","LU1152091754.HKD","BK1515","LU0072913022.USD","LU1226288170.HKD","IE00B543WZ88.USD","LU0880133367.SGD","LU1226287529.USD"],"gpt_icon":0},{"id":"2533688806","title":"Ascletis Pharma to Present Results of Preliminary Studies on Anti-Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2533688806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533688806?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:36","pubTimestamp":1746527794,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  will present the results of its preliminary studies of its ASC47 anti-obesity drug at a congress on obesity in Malaga, Spain, according to a Tuesday filing with the Hong Kong bourse.The company will present a poster and an oral presentation on the drug, which targets adipose tissue or body fat, the filing said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1515","01672","BK1574"],"gpt_icon":0},{"id":"2533507162","title":"BRIEF-Sihuan Pharma Repurchases 20 Million Shares At Average Price Of HK$0.7342 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2533507162","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533507162?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:24","pubTimestamp":1746527055,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Repurchases 20 Million Shares At Average Price Of HK$0.7342 Per ShareMay 6 (Reuters) - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:REPURCHASED 20 MILLION SHARES AT AVERAGE PRICE OF HK$0.7342 PER SHAREFurther company coverage: 0460.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00460","BK1515","BK1593","BK1600"],"gpt_icon":0},{"id":"2533507667","title":"Sihuan Pharma - Repurchased 20 Mln Shares at Average Price of HK$0.7342 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2533507667","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533507667?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:23","pubTimestamp":1746526991,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE135:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1600","BK1515","BK1593","00460","BK1191"],"gpt_icon":0},{"id":"2533502711","title":"Sihuan Pharmaceutical Files Next Day Disclosure Return to HKEX Announcing Repurchase of 20 Million Shares at HKD 0.73-0.74 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2533502711","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533502711?lang=en_us&edition=fundamental","pubTime":"2025-05-06 17:47","pubTimestamp":1746524826,"startTime":"0","endTime":"0","summary":"Sihuan Pharmaceutical Files Next Day Disclosure Return to HKEX Announcing Repurchase of 20 Million Shares at HKD 0.73-0.74 Each. Sihuan Pharmaceutical Holdings Group Ltd. has filed a next day disclosure return to the Hong Kong Stock Exchange, announcing the repurchase of 20,000,000 ordinary shares. These shares were repurchased for holding as treasury shares at a volume-weighted average price of HKD 0.7342 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief on May 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nNDLb8lTqw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","00460","BK1593","BK1600"],"gpt_icon":0},{"id":"2532823894","title":"BRIEF-Sihuan Pharma Says On 30 April And 2 May Repurchased 3.4 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2532823894","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532823894?lang=en_us&edition=fundamental","pubTime":"2025-05-02 22:53","pubTimestamp":1746197584,"startTime":"0","endTime":"0","summary":"BRIEF-Sihuan Pharma Says On 30 April And 2 May Repurchased 3.4 Million SharesMay 2  - Sihuan Pharmaceutical Holdings Group Ltd 0460.HK:ON 30 APRIL AND 2 MAY REPURCHASED 3.4 MILLION SHARES AT AVERAGE PRICE OF HK$0.71 PER SHAREFurther company coverage: 0460.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nFWN3R93MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","BK1600","BK1593","00460"],"gpt_icon":0},{"id":"2532077848","title":"CSPC Pharmaceutical Gets US FDA Nod for Metabolism Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2532077848","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532077848?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:10","pubTimestamp":1746187802,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for JMT202 from the US Food and Drug Administration, a Friday Hong Kong bourse filing said.The drug, which is currently undergoing","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1807302812.USD","LU1226287529.USD","LU1152091168.USD","LU0326950275.SGD","01093","IE0008369823.USD","LU0067412154.USD","LU1951186391.HKD","LU1226287875.USD","BK1191","LU1226287792.SGD","IE00BZ08YS42.EUR","IE0008368742.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","LU1152091754.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU1226288253.USD","LU0880133367.SGD","LU0072913022.USD","SG9999004220.SGD","LU0501845795.SGD","IE00BZ08YT58.USD","LU1008478684.HKD","BK1515","BK1521","LU1960683339.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0140636845.USD"],"gpt_icon":0},{"id":"2532084876","title":"CSPC Pharmaceutical's Phase 2/3 trial for Anti-Cancer Drug Meets Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2532084876","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532084876?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:08","pubTimestamp":1746187681,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  said a phase 2/3 trial of its KN026 anti-cancer drug met the primary endpoint of progression-free survival, according to a Wednesday filing with the Hong Kong bourse.The drug, which treats patients with human epidermal growth factor receptor 2-positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma, is developed by Shanghai JMT-Bio Technology and Jiangsu Alphamab Oncology.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0501845795.SGD","LU1951186391.HKD","LU0067412154.USD","01093","BK1521","SG9999004220.SGD","IE00BZ08YR35.GBP","LU1226287529.USD","BK1515","IE00B543WZ88.USD","IE00BZ08YT58.USD","LU1807302812.USD","LU0140636845.USD","LU1226288170.HKD","BK1191","IE00B5MMRT66.SGD","LU1960683339.HKD","LU1008478684.HKD","LU1152091168.USD","LU0072913022.USD","LU1226287792.SGD","IE0008369823.USD","LU1993786604.SGD","IE0008368742.USD","LU1226288253.USD","LU1226287875.USD","IE00B031HY20.USD","LU1152091754.HKD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2532284883","title":"Sihuan Pharma -  on 30 April and 2 May Repurchased 3.4 Mln Shares at Average Price of HK$0.71 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2532284883","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532284883?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:56","pubTimestamp":1746186977,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nFWN3R93MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00460","BK1191","BK1600","BK1593","BK1515"],"gpt_icon":0},{"id":"2532819392","title":"BRIEF-Ob Holdings Says Unit Entered Into Letters Of Intent With Units of CSPC Pharmaceutical Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2532819392","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532819392?lang=en_us&edition=fundamental","pubTime":"2025-05-02 18:18","pubTimestamp":1746181107,"startTime":"0","endTime":"0","summary":"BRIEF-Ob Holdings Says Unit Entered Into Letters Of Intent With Units of CSPC Pharmaceutical GroupMay 2  - CSPC Pharmaceutical Group Ltd 1093.HK:LETTERS OF INTENT ENTERED INTO BY ORIENT BIOTECH WITH  UNITS OF CSPC PHARMACEUTICAL GROUPOBJECTIVE OF LOI TO DEVELOP, OTHERS & EXPAND APPLICATIONS WITHIN FUNCTIONAL FOOD AND SUPPLEMENT SECTORS ACROSS REGIONAL MARKETSFurther company coverage: 1093.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nFWN3R93LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU1226287792.SGD","LU0880133367.SGD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1951186391.HKD","LU1993786604.SGD","01093","BK1515","LU1960683339.HKD","LU1226287875.USD","LU1226288170.HKD","BK1521","IE00B543WZ88.USD","LU1226287529.USD","LU0067412154.USD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1152091168.USD","LU0140636845.USD","IE00BZ08YR35.GBP","IE00B031HY20.USD","LU1226288253.USD","IE0008368742.USD","LU0326950275.SGD","LU1008478684.HKD","IE0008369823.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0501845795.SGD"],"gpt_icon":1},{"id":"2532819331","title":"CSPC Pharmaceutical -  Jmt202 Obtains Clinical Trial Approval in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2532819331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532819331?lang=en_us&edition=fundamental","pubTime":"2025-05-02 18:16","pubTimestamp":1746181015,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nFWN3R92GR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999004220.SGD","LU1226287529.USD","LU1152091168.USD","LU0880133367.SGD","LU1960683339.HKD","LU0501845795.SGD","LU0140636845.USD","LU1152091754.HKD","IE00BZ08YS42.EUR","LU1226287875.USD","LU0067412154.USD","LU0072913022.USD","LU1226288253.USD","IE0008369823.USD","LU1993786604.SGD","LU1226288170.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","01093","LU1008478684.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU1951186391.HKD","IE0008368742.USD","IE00B543WZ88.USD","LU1226287792.SGD","BK1521","BK1191","LU1807302812.USD","BK1515","IE00B031HY20.USD"],"gpt_icon":0},{"id":"2532281667","title":"Ob Holdings  - Letters of Intent Entered Into by Orient Biotech With  Units of CSPC Pharmaceutical Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2532281667","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532281667?lang=en_us&edition=fundamental","pubTime":"2025-05-02 18:03","pubTimestamp":1746180219,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nFWN3R93LW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1960683339.HKD","LU0501845795.SGD","LU1807302812.USD","LU1152091168.USD","BK1515","IE0008368742.USD","LU0067412154.USD","01093","IE00BZ08YR35.GBP","BK1521","IE0008369823.USD","LU1226288170.HKD","IE00B031HY20.USD","IE00B543WZ88.USD","LU0880133367.SGD","LU1226287792.SGD","LU1152091754.HKD","LU1226287529.USD","BK1191","LU0072913022.USD","LU1226288253.USD","LU0140636845.USD","LU1226287875.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","LU1951186391.HKD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU1008478684.HKD","SG9999004220.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}